|
|
Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-03-0932.
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2003, Vol. 101, No. 6, pp. 2426-2433
TRANSFUSION MEDICINE
Transfusion of pooled buffy coat platelet components prepared
with photochemical pathogen inactivation treatment: the euroSPRITE
trial
Dick van Rhenen,
Hans Gulliksson,
Jean-Pierre Cazenave,
Derwood Pamphilon,
Per Ljungman,
Harald Klüter,
Hans Vermeij,
Mies Kappers-Klunne,
Georgine de
Greef,
Michel Laforet,
Bruno Lioure,
Kathryn Davis,
Stephane Marblie,
Veronique Mayaudon,
Jocelyne Flament,
Maureen Conlan,
Lily Lin,
Peyton Metzel,
Don Buchholz, and
Laurence Corash
From the Sanquin Blood Bank South West Region,
Rotterdam, The Netherlands; Erasmus Medical Center, Rotterdam, The
Netherlands; Huddinge University Hospital Stockholm, Sweden; Institute
for Transfusion Science, Bristol, United Kingdom; Établissement
Français du Sang EFS-Alsace, Strasbourg, France; Institute of
Transfusion Medicine and Immunology, University of Heidelberg,
Faculty of Clinical Medicine, Mannheim, Germany; University of
Washington, Seattle; Baxter Healthcare Corp, Deerfield, IL; and Cerus
Corp, Concord, CA.
A nucleic acid-targeted photochemical treatment (PCT) using
amotosalen HCl (S-59) and ultraviolet A (UVA) light was
developed to inactivate viruses, bacteria, protozoa, and leukocytes in
platelet components. We conducted a controlled, randomized,
double-blinded trial in thrombocytopenic patients requiring repeated
platelet transfusions for up to 56 days of support to evaluate the
therapeutic efficacy and safety of platelet components prepared with
the buffy coat method using this pathogen inactivation process. A total of 103 patients received one or more transfusions of either PCT test
(311 transfusions) or conventional reference (256 transfusions) pooled,
leukoreduced platelet components stored for up to 5 days before
transfusion. More than 50% of the PCT platelet components were stored
for 4 to 5 days prior to transfusion. The mean 1-hour corrected count
increment for up to the first 8 test and reference transfusions was not
statistically significantly different between treatment groups
(13 100 ± 5400 vs 14 900 ± 6200, P = .11). By longitudinal regression analysis for all transfusions, equal doses of
test and reference components did not differ significantly with respect
to the 1-hour (95% confidence interval [CI],  3.1 to
6.1 × 109/L, P = .53) and 24-hour (95%
CI, 1.3 to 6.5 × 109/L, P = .19)
posttransfusion platelet count. Platelet transfusion dose,
pretransfusion storage duration, and patient size were significant covariates (P < .001) for posttransfusion platelet
counts. Clinical hemostasis, hemorrhagic adverse events, and overall
adverse events were not different between the treatment groups.
Platelet components prepared with PCT offer the potential to further
improve the safety of platelet transfusion using technology compatible
with current methods to prepare buffy coat platelet components.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.-L. H. Kerkhoffs, J. C. Eikenboom, M. S. Schipperus, R. J. van Wordragen-Vlaswinkel, R. Brand, M. S. Harvey, R. R. de Vries, R. Barge, D. J. van Rhenen, and A. Brand
A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma
Blood,
November 1, 2006;
108(9):
3210 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Mintz, N. M. Bass, L. D. Petz, R. Steadman, M. Streiff, J. McCullough, S. Burks, D. Wages, S. Van Doren, and L. Corash
Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease
Blood,
May 1, 2006;
107(9):
3753 - 3760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. McCullough, D. H. Vesole, R. J. Benjamin, S. J. Slichter, A. Pineda, E. Snyder, E. A. Stadtmauer, I. Lopez-Plaza, S. Coutre, R. G. Strauss, et al.
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
Blood,
September 1, 2004;
104(5):
1534 - 1541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
